BioSpace News Archive

SinguLab® announced enhancements to its suite of capabilities and services that assist clinical providers in the effective treatment and management of Urinary Tract Infections.

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its participation in and sponsor support of the 4th Symposium on Infectious Diseases in the Immunocompromised Host, being held April 30 to May 2, 2023, in Seattle, Washington and hosted by the Fred Hutchinson Cancer Center.

Corza Medical announced that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company to acquire the TachoSil manufacturing operations in Linz, Austria.

Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York.

Moss Genomics Inc. (CSE: MOSS) (“Moss” or the “Company”), a consumer genomics and gut microbiome company based in Vancouver, British Columbia announces the introduction of its Pain and Inflammation report which can be ordered directly to your home via the Company’s online platform

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the “Company”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD),

Bolt Biotherapeutics, Inc. announced that it will present a poster with clinical data from its completed Phase 1 dose-escalation study of BDC-1001 at the 2023 American Society for Clinical Oncology Annual Meeting.

IN8bio, Inc. today announced an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from June 2-6, 2023.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6.